Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lead to regulatory ...

The European Commission has cleared AZ's PD-L1 inhibitor Imfinzi (durvalumab) alongside PARP inhibitor Lynparza (olaparib) for patients with primary advanced or recurrent endometrial cancer with ...

Sales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso, and Imfinzi — and diabetes medicine Farxiga, are expected to have driven the company’s top line in the ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca has launched new lawsuits against four generic drug manufacturers in an ongoing patent battle over its cancer drug Lynparza (olaparib), approved to treat ovarian, pancreatic ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $3.46 billion in the first nine months of 2024, up 22% year over year at constant exchange rates ...

AstraZeneca’s Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat a new subset of breast cancer patients. The health technology assessment ...